Superiority of Rocuronium Reversed with Sugammadex for Overweight and Obese Patients Anesthesia: A Randomized Controlled Trial

Trial Profile

Superiority of Rocuronium Reversed with Sugammadex for Overweight and Obese Patients Anesthesia: A Randomized Controlled Trial

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Rocuronium bromide (Primary) ; Sugammadex (Primary) ; Cisatracurium besilate; Neostigmine
  • Indications Neuromuscular blockade
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Apr 2018 Planned End Date changed from 1 Apr 2019 to 1 Jul 2020.
    • 12 Apr 2018 Planned initiation date changed to 1 Jul 2018.
    • 05 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top